Icagen/McNeil’s ICA-17043 Is Lead Candidate To Be Second Sickle Cell Drug On Market

The compound is poised to begin Phase III; J&J subsidiary McNeil entered a U.S. co-development and commercialization partnership with innovator Icagen for the oral once-daily chronic treatment in June. The orphan drug has fast-track status at FDA.